Contact
searchSearch
HMP Global
Login

HRR Biological Pathways Reviews

Videos

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer
12/12/2023
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 3 of...
12/12/2023
Oncology
Shahneen Sandhu, MBBS, Peter MacCallum Cancer Centre
Videos
Prevalence of DNA Repair Defects Among Patients With Metastatic Prostate Cancer
11/02/2023
Shahneen Sandhu, MBBS
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.
In a prospective observational...
11/02/2023
Oncology
Elena Castro, MD, PhD Hospital Universitario 12 de Octubre
Videos
Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
11/01/2023
Elena Castro, MD, PhD
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.
Elena Castro, MD, shares final...
11/01/2023
Oncology
Eleni Efstathiou, MD, Houston Methodist Cancer Center
Videos
Niraparib Plus Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer and HRR Alterations
02/27/2023
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...
At 2023 ASCO Genitourinary...
02/27/2023
Oncology
Kirollos Hanna, PharmD
Videos
Darolutamide Plus ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
03/25/2026
Kirollos Hanna, PharmD, discusses results from the phase 3 ARANOTE trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Kirollos Hanna, PharmD, discusses results from the phase 3 ARANOTE trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Kirollos Hanna, PharmD,...
03/25/2026
Oncology
Daniel Rosas, MD
Videos
Rethinking the Role of Second-Line Chemotherapy in Advanced Lung Cancer
03/20/2026
Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Daniel Rosas, MD, discusses...
03/20/2026
Oncology
Sarah Premji, MD
Videos
Clinical Differences Among Oral SERDs in HR-Positive, HER2-Negative Breast Cancer
03/20/2026
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses...
03/20/2026
Oncology
Edward Garon, MD
Videos
Biomarkers as the Foundation of Tumor-Agnostic Therapy
03/19/2026
Edward B. Garon, MD, MS
Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Edward Garon, MD, discusses the...
03/19/2026
Oncology
Julio Chavez, MD
Videos
Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL
03/19/2026
Julio Chavez, MD
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews...
03/19/2026
Oncology
Richard Furman, MD
Videos
Immature Data Limit Conclusions on Continuous vs Fixed-Duration Frontline CLL Therapies
03/19/2026
Richard Furman, MD
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naĂŻve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naĂŻve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses...
03/19/2026
Oncology
Adam Brufsky, MD, PhD
Videos
Evaluating ctDNA-Guided Therapy in Early-Stage Breast Cancer
03/19/2026
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.
Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.
Adam Brufsky, MD, PhD, discusses...
03/19/2026
Oncology
Angeles Secord, MD
Videos
Refining HRD-Guided PARP Inhibitor Use in Advanced Ovarian Cancer
03/19/2026
Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Angeles Secord, MD, discusses...
03/19/2026
Oncology
Midun Mala, MD
Videos
Evaluating Adjuvant HAI Pump Therapy in Patients With Resected Colorectal Liver Metastases
03/19/2026
Midhun Malla, MD, MS
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use...
03/19/2026
Oncology
Arnab Basu, MD
Videos
Emerging Bladder Preservation Strategies for Patients With Muscle-Invasive Bladder Cancer
03/19/2026
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses...
03/19/2026
Oncology

News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology

Quizzes

Quiz
Tucatinib Plus Trastuzumab for HER2-Posititive Metastatic Colorectal Cancer
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
Serum LDH and α-HBDH Levels in SCLC
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
Predictive Accuracy of Whole-Brain Radiotherapy Response in SCLC With Brain Metastases
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
Safusidenib Erbumine for IDH1-Mutated Glioma
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naĂŻve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naĂŻve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
Venetoclax Plus CACAG Therapy for Relapsed/Refractory Acute Myeloid Leukemia
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
High-Risk Stratification in Cutaneous Squamous Cell Carcinoma
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology
Quiz
ISL1 as a Predictive Biomarker for Lurbinectedin Efficacy in Small Cell Lung Cancer
02/05/2026
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging...
02/05/2026
Oncology
Quiz
Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology
Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology
OLN

HRR

ALIASES

Human recombination repair

References

Homologous recombination repair (HHR) is a DNA repair mechanism that removes damaged DNA by acting on double-strand breaks, interstrand crosslinks, and other kinds of DNA damage.1 DNA damage is repaired with high fidelity by correcting damage with information copied from a homologous undamaged molecule.2 Defects in HRR are present in some cancers.3

Recent News

Conference Coverage
Olaparib Plus Abiraterone and Prednisone Improved Progression-Free Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations
01/25/2024
Allison Casey
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial, olaparib plus abiraterone/prednisone improved the progression-free survival among patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM mutations, compared to either agent alone or...
According to a phase 2 trial,...
01/25/2024
Oncology
News
Novel Genomic Instability Scar Test for Detecting Homologous Repair Deficiency, Predicting Olaparib Sensitivity Among Patients With Ovarian Cancer
10/16/2023
Allison Casey
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed Genomic Instability Scar test was determined to reliably detect HRD and predict olaparib sensitivity among patients with ovarian cancer, according to a study.
The novel, academic-developed...
10/16/2023
Oncology
News
PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations for Metastatic Castration-Resistant Prostate Cancer
09/26/2023
Allison Casey
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and meta-analysis confirmed the efficacy and safety of PARP inhibitor plus androgen receptor signaling inhibitor combinations for the treatment of patients with metastatic castration-resistant prostate cancer.
A quantitative synthesis and...
09/26/2023
Oncology
News
Niraparib Plus Abiraterone Acetate and Prednisone Continues to Benefit Patients with HRR-Altered Metastatic Castration-Resistant Prostate Cancer
09/14/2023
Allison Casey
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis of the phase 3 MAGNITUDE trial, niraparib plus abiraterone acetate and prednisone improved the radiographic progression-free survival of patients with metastatic castration-resistant prostate cancer and HRR...
In the second interim analysis...
09/14/2023
Oncology
News
Maintenance Niraparib Extended PFS Among Patients With Advanced Ovarian Cancer
07/26/2023
Stephanie Holland
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the phase 3 PRIME study, first-line, maintenance niraparib prolonged PFS with an individualized starting dose that was both safe and effective among patients with newly diagnosed, advanced ovarian cancer.
According to results from the...
07/26/2023
Oncology
News
Talazoparib With Enzalutamide Approved for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
06/21/2023
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA granted approval to talazoparib plus enzalutamide for the treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer.
On June 20, 2023, the US FDA...
06/21/2023
Oncology
News
FDA Approves Olaparib for HRR Gene-Mutated mCRPC
05/20/2020
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC that progressed following prior therapy.
The FDA has approved olaparib...
05/20/2020
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use